Home All Products SMA
SMA
SMA

SMA

SMA is a synthetic peptide analog used in laboratory studies investigating GLP-1 receptor signaling. It is structurally modified to resist enzymatic degradation and to exhibit extended circulating stability, which allows researchers to examine prolonged GLP-1–related biochemical pathways.

GLP-1 Receptor Pathways
SMA is commonly used in research models to explore:

  • Pancreatic GLP-1 receptor signaling, including pathways involved in glucose-dependent insulin secretion.
  • Glucagon modulation via α-cell interactions in in-vitro and ex-vivo systems.

Central Appetite & Satiety Signaling
Studies evaluate GLP-1 receptor activity in:

  • Hypothalamic nuclei involved in food-intake signaling.
  • Brainstem/postrema circuits associated with ingestive behavior and neuroendocrine communication.

Gastrointestinal Signaling Models
Research explores:

  • Delayed gastric emptying pathways
  • Nutrient sensing mechanisms
  • Gut–brain neurochemical feedback loops

Metabolic & Cellular Pathways
SMA is used in metabolic research to study:

  • β-cell signaling and secretory pathways
  • Lipid and energy-utilization models
  • Interactions with BDNF, neuroinflammation, and oxidative-stress pathways

Structural Properties

SMA incorporates:

  • Amino-substitution at position 8, enhancing resistance to DPP-4.
  • Fatty-acid side-chain conjugation, supporting albumin-binding studies and prolonged half-life modeling.


SMA itself is not investigational.
It is FDA-approved as a prescription medication under specific branded products:

  • Ozempic® – diabetes (T2DM)
  • Wegovy® – chronic weight management
  • Rybelsus® – oral semaglutide for diabetes


Those products are fully regulated prescription drugs, manufactured under strict FDA oversight by Novo Nordisk.

Clinical References

  1. Davies, M. et al. (2021). Investigations of GLP-1 receptor agonism and metabolic signaling.
  2. Gøtzsche, W. T., et al. (2022). Long-acting peptide analogs and extended signaling models.
  3. Nauck, M. A., et al. (2019). Structural and pharmacologic characteristics of GLP-1 analogs.
  4. Rubino, D., et al. (2021). Mechanistic models evaluating GLP-1 receptor pathways and metabolic adaptation.
  5. Blonde, L., et al. (2021). Research on incretin-based peptide mechanisms.
  • Glycemic Control: HbA1c reduction of 1.5–2.2%; 60–70% achieving HbA1c <7%
  • Weight Loss: Mean 15.2% body weight reduction; 40% losing ≥20%
  • Cardiovascular Protection: 26% reduction in major CV events; improved endothelial function
  • Appetite Suppression: Central GLP-1 receptor activation reduces caloric intake
  • Insulin Sensitivity: Improved HOMA-IR; maintains β-cell function
  • Convenient Dosing: Once-weekly subcutaneous or daily oral administration
  • Multi-Organ Benefits: Kidney, liver, and potential neuroprotection
  • Safety Profile: Mild-to-moderate GI side effects, usually resolving with dose titration
  • Sustained Efficacy: Long-term weight and glycemic control maintained for up to 2 years

$120.00

Per Unit
In stock

Free Shipping on All Orders $1000+